{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:30:54Z","timestamp":1707525054463},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,20]]},"DOI":"10.7759\/cureus.40689","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T14:57:15Z","timestamp":1687273035000},"source":"Crossref","is-referenced-by-count":0,"title":["Vaginal Herpes Zoster While Under Treatment for Relapsing-Remitting Multiple Sclerosis With Diroximel Fumarate"],"prefix":"10.7759","author":[{"given":"Sedat","family":"G\u00fcl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeenah F","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey","family":"McGraw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Multiple sclerosis: prevalence and impact","volume":"29","author":"Gilmour H","year":"2018","unstructured":"Gilmour H, Ramage-Morin PL, Wong SL. Multiple sclerosis: prevalence and impact. Health Rep. 2018, 29:3-8.","journal-title":"Health Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.22074\/cellj.2016.4867","article-title":"Multiple sclerosis: pathogenesis, symptoms, diagnoses, and cell-based therapy","volume":"19","author":"Ghasemi N","year":"2017","unstructured":"Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses, and cell-based therapy. Cell J. 2017, 19:1-10. 10.22074\/cellj.2016.4867","journal-title":"Cell J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01367-1","article-title":"Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy","volume":"37","author":"Bowen J","year":"2020","unstructured":"Bowen J, Mehta R, Pelletier C, Tian M, Noxon V, Johnson BH, Bonafede M. Treatment patterns among patients with multiple sclerosis initiating second-line disease-modifying therapy. Adv Ther. 2020, 37:3163-3177. 10.1007\/s12325-020-01367-1","journal-title":"Adv Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02164-8","article-title":"Health-related quality of life with diroximel fumarate in patients with relapsing forms of multiple sclerosis: findings from qualitative research using patient interviews","volume":"39","author":"Gudesblatt M","year":"2022","unstructured":"Gudesblatt M, Roman C, Singer BA, et al.. Health-related quality of life with diroximel fumarate in patients with relapsing forms of multiple sclerosis: findings from qualitative research using patient interviews. Adv Ther. 2022, 39:3199-3213. 10.1007\/s12325-022-02164-8","journal-title":"Adv Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100306","article-title":"Dimethyl fumarate and its esters: a drug with broad clinical utility?","volume":"13","author":"Kourakis S","year":"2020","unstructured":"Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E. Dimethyl fumarate and its esters: a drug with broad clinical utility?. Pharmaceuticals (Basel). 2020, 13:306. 10.3390\/ph13100306","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study","volume":"34","author":"Naismith RT","year":"2020","unstructured":"Naismith RT, Wundes A, Ziemssen T, et al.. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs. 2020, 34:185-196. 10.1007\/s40263-020-00700-0","journal-title":"CNS Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02068-7","article-title":"Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase\u00a03 EVOLVE-MS-1 study","volume":"39","author":"Wray S","year":"2022","unstructured":"Wray S, Then Bergh F, Wundes A, et al.. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase\u00a03 EVOLVE-MS-1 study. Adv Ther. 2022, 39:1810-1831. 10.1007\/s12325-022-02068-7","journal-title":"Adv Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/v14020192","article-title":"Herpes zoster: a review of clinical manifestations and management","volume":"14","author":"Patil A","year":"2022","unstructured":"Patil A, Goldust M, Wollina U. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022, 14:192. 10.3390\/v14020192","journal-title":"Viruses"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin MT","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD, et al.. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019, 92:e1029-e1040. 10.1212\/WNL.0000000000007035","journal-title":"Neurology"},{"key":"ref10","article-title":"An unusual presentation of herpes zoster","volume":"13","author":"Tung RC","year":"2020","unstructured":"Tung RC, Shaaban A, Kim M, Cristiano P. An unusual presentation of herpes zoster. Kans J Med. 2020, 13:19-20.","journal-title":"Kans J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1090","article-title":"Herpes zoster risk in immunocompromised adults in the United States: a systematic review","volume":"71","author":"McKay SL","year":"2020","unstructured":"McKay SL, Guo A, Pergam SA, Dooling K. Herpes zoster risk in immunocompromised adults in the United States: a systematic review. Clin Infect Dis. 2020, 71:e125-e134. 10.1093\/cid\/ciz1090","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000001465","article-title":"Genital herpes zoster: a rare location that can mimic genital herpes","volume":"49","author":"Magdaleno-Tapial J","year":"2022","unstructured":"Magdaleno-Tapial J, Hern\u00e1ndez-Bel P, Ortiz-Salvador JM, L\u00f3pez-Mart\u00ed C, Mart\u00ednez-Dom\u00e9nech \u00c1, Garc\u00eda-Legaz-Mart\u00ednez M, P\u00e9rez-Ferriols A. Genital herpes zoster: a rare location that can mimic genital herpes. Sex Transm Dis. 2022, 49:e34-e36. 10.1097\/OLQ.0000000000001465","journal-title":"Sex Transm Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/160067-vaginal-herpes-zoster-while-under-treatment-for-relapsing-remitting-multiple-sclerosis-with-diroximel-fumarate","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:04:04Z","timestamp":1707509044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/160067-vaginal-herpes-zoster-while-under-treatment-for-relapsing-remitting-multiple-sclerosis-with-diroximel-fumarate"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,20]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.40689","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,20]]}}}